A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

November 30, 2008

Conditions
Multiple Sclerosis
Interventions
DRUG

oral lipoic acid (LA)

A single 1200 mg dose of oral LA will be administered.

DRUG

lipoic acid (LA) with fish oil and LA without fish oil

Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.

DRUG

R lipoic acid

A single oral dose of 1200mg R enantiomer LA will be administered.

Trial Locations (1)

97239

Oregon Health and Science University Multiple Sclerosis Dept., Portland

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Oregon Health and Science University

OTHER

NCT00676156 - A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis | Biotech Hunter | Biotech Hunter